AbbVie Inc. (ABBV)

NYQ – Real vaqt narxi. Valyuta: USD

253.35

+10.21 (4.20%)

Yopilishda: Jun 26, 2026, 4:06 PM EDT

252.98

-0.37 (-0.15%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

16.06.2026

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

AbbVie maintains strong momentum in immunology, with Skyrizi and Rinvoq offsetting Humira declines and driving double-digit revenue growth. I reaffirm a 'Strong Buy' rating, supported by expanding indications for Skyrizi in Crohn's Disease and Rinvoq in alopecia areata and vitiligo. Skyrizi's subcutaneous induction for Crohn's Disease, validated by phase 3 AFFIRM data, targets further market share and revenue acceleration.

16.06.2026

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer.

16.06.2026

AbbVie Stock Will Hit $300 on This Date

AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare's most underrated growth stories.

16.06.2026

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

16.06.2026

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1" This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1 IRVINE, Calif., June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1 Neck wrinkles may develop due to natural aging, sun damage, weight loss, or "tech-neck" caused by the head-down position used for phones, tablets, and books.1 SKINVIVE by JUVÉDERM® reduces neck lines formed by tech-neck by helping the skin retain its natural moisture, softness, and smoothness.1 Treatment with SKINVIVE by JUVÉDERM® is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula.

12.06.2026

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.

12.06.2026

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs.

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
ABBV	Citigroup	Neutral	undefined >> $205	May 14th 2025
ABBV	Cantor Fitzgerald	Overweight	undefined >> $210	April 22nd 2025
ABBV	Daiwa Securities	Neutral	undefined >> $180	December 5th 2024
ABBV	Leerink Partners	Outperform	undefined >> $206	November 22nd 2024
ABBV	Wolfe Research	Outperform	undefined >> $205	November 15th 2024
ABBV	Argus	Buy	undefined >> undefined	November 4th 2024
ABBV	Bernstein	Market Perform	undefined >> $203	October 17th 2024
ABBV	HSBC Securities	Buy	undefined >> $185	June 5th 2024

AbbVie Inc. (ABBV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbbVie Inc. (ABBV)

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

AbbVie Stock Will Hit $300 on This Date

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

AbbVie Stock Will Hit $300 on This Date

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Search stocks

AbbVie Inc. (ABBV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbbVie Inc. (ABBV)

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

AbbVie Stock Will Hit $300 on This Date

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

AbbVie Stock Will Hit $300 on This Date

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026